Synagis 50 mg (Palivizumab SOLUTION) 50 MG

SYNAGIS 50 MG is a solution containing palivizumab, used for respiratory syncytial virus (RSV) prevention. This intramuscular injection is manufactured by AstraZeneca Canada Inc.

Strength

50 MG

Pack Size

0.5ML

Manufacturer / TM Owner

ASTRAZENECA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

SYNAGIS 50 MG is primarily used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk infants and children. Palivizumab, the active ingredient, is designed to help reduce the risk of RSV-related hospitalizations. This medication is often recommended for use during RSV season or for those with a history of severe RSV infections.

Side Effects

Common effects of SYNAGIS 50 MG may include mild reactions at the injection site, such as redness or swelling. Some individuals might experience fever or irritability following administration. These effects are generally mild and temporary.

Precautions & Warnings

SYNAGIS 50 MG should be administered by healthcare professionals experienced in intramuscular injections. It is important to inform your healthcare provider about any allergies or medical conditions before use. Always follow the prescribed guidelines for storage and handling to maintain the medication's efficacy.

Avoid Interactions

SYNAGIS 50 MG may interact with other medications, so it is crucial to discuss all current treatments with your healthcare provider. Specific interactions with palivizumab are not well-documented, but caution is advised when combining with other immunosuppressive therapies.

Frequently Asked Questions

SYNAGIS 50 MG is used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk infants and children.

SYNAGIS 50 MG is administered as an intramuscular injection, typically by a healthcare professional.

Common side effects may include mild reactions at the injection site, such as redness or swelling, and occasionally fever or irritability.

Individuals with known allergies to palivizumab or any of the ingredients in SYNAGIS 50 MG should avoid using this medication.

It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.